Applications of machine learning and computational intelligence to drug discovery and development

Transfer learning using attentions across atomic systems with graph neural networks (TAAG)

Recent advances in Graph Neural Networks (GNNs) have transformed the space of molecular and catalyst discovery. Despite the fact that the underlying physics across these domains remain the same, most prior work has focused on building domain-specific models either in small molecules or in materials. However, building large datasets across all domains is computationally expensive; therefore, the use of transfer learning (TL) to generalize to different domains is a promising but under-explored approach to this problem. To evaluate this hypothesis, we use a model that is pretrained on the Open Catalyst Dataset (OC20), and we study the model's behavior when fine-tuned for a set of different datasets and tasks. This includes MD17, the *CO adsorbate dataset, and OC20 across different tasks. Through extensive TL experiments, we demonstrate that the initial layers of GNNs learn a more basic representation that is consistent across domains, whereas the final layers learn more task-specific features. Moreover, these well-known strategies show significant improvement over the non-pretrained models for in-domain tasks with improvements of 53% and 17% for the *CO dataset and across the Open Catalyst Project (OCP) task, respectively. TL approaches result in up to 4× speedup in model training depending on the target data and task. However, these do not perform well for the MD17 dataset, resulting in worse performance than the non-pretrained model for few molecules. Based on these observations, we propose transfer learning using attentions across atomic systems with graph Neural Networks (TAAG), an attention-based approach that adapts to prioritize and transfer important features from the interaction layers of GNNs. The proposed method outperforms the best TL approach for out-of-domain datasets, such as MD17, and gives a mean improvement of 6% over a model trained from scratch.

Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery

Artificial Intelligence revolutionizes the drug development process that can quickly identify potential biologically active compounds from millions of candidate within a short period. The present review is an overview based on some applications of Machine Learning based tools, such as GOLD, Deep PVP, LIB SVM, etc. and the algorithms involved such as support vector machine (SVM), random forest (RF), decision tree and Artificial Neural Network (ANN), etc. at various stages of drug designing and development. These techniques can be employed in SNP discoveries, drug repurposing, ligand-based drug design (LBDD), Ligand-based Virtual Screening (LBVS) and Structure- based Virtual Screening (SBVS), Lead identification, quantitative structure-activity relationship (QSAR) modeling, and ADMET analysis. It is demonstrated that SVM exhibited better performance in indicating that the classification model will have great applications on human intestinal absorption (HIA) predictions. Successful cases have been reported which demonstrate the efficiency of SVM and RF models in identifying JFD00950 as a novel compound targeting against a colon cancer cell line, DLD-1, by inhibition of FEN1 cytotoxic and cleavage activity. Furthermore, a QSAR model was also used to predict flavonoid inhibitory effects on AR activity as a potent treatment for diabetes mellitus (DM), using ANN. Hence, in the era of big data, ML approaches have been evolved as a powerful and efficient way to deal with the huge amounts of generated data from modern drug discovery to model small-molecule drugs, gene biomarkers and identifying the novel drug targets for various diseases.

Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site

A series of 2-aminobenzimidazole analogues have been synthesised and tested for binding to a previously established RNA target for viral translation inhibitors in the internal ribosome entry site (IRES) of the hepatitis C virus (HCV). Synthesis of new inhibitor compounds followed a highly convergent strategy which allowed for incorporation of diverse tertiary amino substituents in high overall yields (eight-steps, 4–22%). Structure–activity relationship (SAR) studies focussed on the tertiary amine substituent involved in hydrogen bonding with the RNA backbone at the inhibitor binding site. The SAR study was further correlated with in silico docking experiments. Analogous compounds showed promising activities (half maximal effective concentration, EC50: 21–89µM). Structures of the synthesised analogues and a correlation to their mode of binding, provided the opportunity to explore parameters required for selective targeting of the HCV IRES at the subdomain IIa which acts as an RNA conformational switch in HCV translation.

Big Data and Artificial Intelligence Modeling for Drug Discovery

Due to the massive data sets available for drug candidates, modern drug discovery has advanced to the big data era. Central to this shift is the development of artificial intelligence approaches to implementing innovative modeling based on the dynamic, heterogeneous, and large nature of drug data sets. As a result, recently developed artificial intelligence approaches such as deep learning and relevant modeling studies provide new solutions to efficacy and safety evaluations of drug candidates based on big data modeling and analysis. The resulting models provided deep insights into the continuum from chemical structure to in vitro, in vivo, and clinical outcomes. The relevant novel data mining, curation, and management techniques provided critical support to recent modeling studies. In summary, the new advancement of artificial intelligence in the big data era has paved the road to future rational drug development and optimization, which will have a significant impact on drug discovery procedures and, eventually, public health.

Bridging paradigms: hybrid mechanistic-discriminative predictive models

Many disease processes are extremely complex and characterized by multiple stochastic processes interacting simultaneously. Current analytical approaches have included mechanistic models and machine learning (ML), which are often treated as orthogonal viewpoints. However, to facilitate truly personalized medicine, new perspectives may be required. This paper reviews the use of both mechanistic models and ML in healthcare as well as emerging hybrid methods, which are an exciting and promising approach for biologically based, yet data-driven advanced intelligent systems.